The Medical Director role will be responsible for supporting the product through its life cycle for hidradenitis suppurativa (HS) via leadership, mentorship, and execution of the Medical Affairs strategic vision. Together with the Executive Director of Medical Affairs, this role will be responsible for supporting all relevant commercialization activities including launch activities for HS. This individual will play a meaningful role in engagement of the external medical community.
Responsible for providing therapeutic area/product expertise for Solid Tumors (CRC, Melanoma and GYN) as well as Early Pipeline support across a broad range of Medical customer segments and initiatives in VA, NC, SC and Washington DC. Delivers approved medical content about Pfizer medicines and relevant topics in the designated therapeutic area. Provides truthful, accurate, and scientifically supported information in response to direct unsolicited medical requests from HCPs.
This role focuses on the rare bone disease franchise, specifically preparing for the potential commercialization of a monoclonal antibody therapy for Osteogenesis Imperfecta (OI) and supporting Crysvita for XLH. Reporting to the VP Global/US Medical Affairs and Strategy, the Executive Director will establish partnerships with key opinion leaders, lead scientific education, and provide strategic medical expertise to the program and commercialization teams.